ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.
Feldinger K, et al. Among authors: leek r.
Oncotarget. 2014 Aug 30;5(16):6633-46. doi: 10.18632/oncotarget.1955.
Oncotarget. 2014.
PMID: 24952873
Free PMC article.